Revenue → Gross profit: $57.1BDiabetes care → Revenue: $49.1BGLP-1 → Diabetes care: $36.7BGross profit → Operating cost: $33.4BGross profit → Operating profit: $23.7BObesity care → Revenue: $21.1BOperating profit → Net profit: $18.2BRevenue → Cost of sales: $17.9BOperating cost → Sales & distribution: $16.0BOperating cost → R&D: $15.4BInsulin → Diabetes care: $12.0BOperating profit → Tax: $5.5BRare disease → Revenue: $4.7BOperating cost → Administrative costs: $1.9BFinancial items → Net profit: $1.8BOther diabetes → Diabetes care: $0.4BOperating cost → Other costs: $0.1BAdministrative costs$1.9B36% Y/YCost of sales$17.9B58% Y/YDiabetes care$49.1B-5% Y/YFinancial items$1.8B415% Y/YGLP-1$36.7B-4% Y/YGross profit$57.1B-5% Y/YInsulin$12.0B-6% Y/YNet profit$20.0B380% Y/YObesity care$21.1B4% Y/YOperating cost$33.4B28% Y/YOperating profit$23.7B-30% Y/YOther costs$0.1B16% Y/YOther diabetes$0.4B-7% Y/YR&D$15.4B62% Y/YRare disease$4.7B-4% Y/YRevenue$75.0B-2% Y/YSales & distribution$16.0B5% Y/YTax$5.5B-22% Y/YNovo Nordisk Q3 FY25 Income Statementcreated with SankeyArt.com
2023
Full Year
2024
H1
2025
Q1 Q3
Copy and edit diagram